Skip to content

Prospective Study of Colon Serrated Polyps

Prospective Study of Colon Serrated Polyps

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02332785
Enrollment
10000
Registered
2015-01-07
Start date
2014-11-30
Completion date
2027-11-30
Last updated
2019-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Polyps

Keywords

Colon Serrated Polyps, Serrated polyp, Hyperplastic polyps above sigmoid colon, Sessile serrated adenoma, Traditional serrated adenoma, Colonoscopy, Endoscopy, Data collection, Data review

Brief summary

With this study, the investigators plan to review the clinical, epidemiology, pathology, and endoscopic features of colon serrated lesions as well as outcome of endoscopic resection of these lesions. The findings will help us define the natural history of colon serrated lesions, develop techniques for endoscopic management of patients with serrated lesions, and identity areas for improvement. The data will be used for continuing quality improvement and presenting our outcomes at academic meetings and publishing our results in peer reviewed journals.

Detailed description

Our goal is to collect data from our endoscopy reports and electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025. Specific variable to be reviewed: 1. Patient Demographics: Age, Sex, Race, Height, Weight, BMI (patient privacy will be acknowledged). 2. Indications for Colonoscopy (screening, surveillance, symptoms or tertiary referral \[EMR\]). 3. Comorbid conditions: cancer and surgical history, medical conditions. 4. Colonoscopy procedure: Quality of colon preparation (using the Boston Bowel Preparation Scale) 0 - 3 for each section of the colon (Ascending, Transverse, Descending and Total Colon), cecal intubation rate, cecal intubation and total procedure time, type of colonoscope (if CO2 was used in the procedure and techniques for colonoscope insertion, including position changes. 5. Examination findings: Number of polyps and nature of polyps removed (site, size, surface, vascular pattern); type of polyp removed (serrated and sessile (flat); optical features and histology of polyps. 6. Resection techniques: Biopsy, snare resection, endoscopic mucosal resection, endoscopic submucosal dissection etc. 7. Including Pathology report findings so that a comparison can be made of the optical features and actual pathology report. 8. Outcomes of colonoscopy: Complete or incomplete resection, local recurrence, need for surgery, etc. 9. Outcome of colonoscopy: Complications (Bleeding and perforation).

Interventions

OTHERData Collection

Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1\. All Patients with a serrated polyp (Hyperplastic polyps above sigmoid colon, sessile serrated adenoma, traditional serrated adenoma)

Exclusion criteria

N/A

Design outcomes

Primary

MeasureTime frameDescription
Data Review of Colonoscopic Resection of Serrated Colon Polyps1 dayDescriptive tables presented for demographics, polyp counts, colonoscopy experiences, polyp removals and findings. Proportions presented with 95% confidence intervals. Continuous values such as age and times presented with median, minimum and maximum. Comparisons among patient subgroups made with chi-square tests for categorical data and t-tests or the non-parametric alternative, Wilcoxon tests, to compare continuous measures. Graphics such as box plots, trellis plots, bar graphs, or stacked bar graphs used to describe distributions overall and among subgroups.

Countries

United States

Contacts

Primary ContactGottumukkala S. Raju, MD
GSRaju@mdanderson.org713-563-4377

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026